Clinical Trial Update: Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of tasquinimod in Asian chemo-naïve patients with metastatic castration-resistant prostate cancer was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Tasquinimod (tasquinimod)

Snippet

Sponsor: Ipsen | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 3 | Status: TERMINATED | Results posted: 2021-04-23